Garwood Medical Devices, Inc. (GMD), is a pioneering medical device company driven by a singular mission: "To Advance Infection Control Through Innovation." At GMD, they're committed to revolutionizing infection control with patented technologies designed to provide highly effective, efficient, and measurable electrical stimulation treatments for peri-prosthetic infections. Their groundbreaking BioPrax™ technology targets infections on implants, even those caused by antibiotic-resistant bacteria. With a dedication to Advancing Implant Infection Control Through InnovationTM, GMD seeks to make a tangible difference in patient outcomes and ultimately save lives.

The inspiration behind Garwood Medical Devices comes from the legacy of two esteemed veterans after whom the company is named. These veterans, both named Garwood, were the father and brother of the company's President and CEO, Wayne D. Bacon. Their memory serves as a guiding light for GMD's mission to provide innovative solutions for patients suffering from bacterial biofilm infections.

Founded with a clear purpose, Garwood Medical Devices aims to offer a lifeline to all patients grappling with bacterial biofilm infections. They utilize cutting-edge technologies that have the potential to significantly improve the current standard of care. By focusing on practical innovation and impactful solutions, GMD strives to make a meaningful difference in the lives of patients worldwide.

BioPrax™: Pioneering Infection Control for Orthopedic Implants

Garwood Medical Devices introduces BioPrax™, a revolutionary solution aimed at combating biofilm infections on prosthetic knee implants. This groundbreaking technology represents a significant stride forward in early intervention procedures while upholding the existing standard of care. Let's delve into the key features and intricate workings of BioPrax™, a beacon of hope for patients and healthcare providers alike.

Key Features of BioPrax™

FDA Breakthrough Designation: BioPrax™ has earned the prestigious FDA Breakthrough Device Designation, underscoring its potential to provide superior treatment for life-threatening or irreversibly debilitating conditions. This recognition highlights the transformative impact of BioPrax™ on patient care and outcomes.

High Effectiveness: Extensive in vivo animal and in vitro lab studies have demonstrated BioPrax™'s exceptional effectiveness, boasting up to a remarkable 99.6% efficacy in eliminating biofilms. This includes notoriously challenging drug-resistant bacteria such as MRSA and E. Coli, signifying BioPrax™'s potency in addressing complex infections.

Preservation of Implant: One of BioPrax™'s remarkable attributes is its potential to preserve the original implant, thereby minimizing the need for extensive surgical interventions. By safeguarding the integrity of the implant, BioPrax™ offers a promising avenue for enhancing patient outcomes while reducing healthcare costs.

Ease of Use: Designed with simplicity in mind, BioPrax™ features a user-friendly touchscreen interface that requires minimal training. This intuitive design ensures accessibility for healthcare professionals across diverse clinical settings, facilitating seamless integration into existing medical practices.

Minimally Invasive: Emphasizing patient comfort and recovery, BioPrax™ employs a minimally invasive procedure. By minimizing tissue trauma and postoperative complications, BioPrax™ enhances patient satisfaction and promotes expedited recovery, underscoring its patient-centric approach.

How BioPrax™ Works

Targeting Biofilm Infections: BioPrax™ specifically targets and eliminates biofilm infections, addressing the underlying cause of implant-related complications. By eradicating biofilms, BioPrax™ disrupts the microbial environment, thereby facilitating infection clearance and promoting tissue healing.

Application Process: The application of BioPrax™ begins with the insertion of a needle through the skin until it makes contact with the metal implant. Once positioned, the treatment process is initiated through a simplistic touchscreen interface, ensuring precision and accuracy in delivery.

Electrochemical Reaction: Leveraging low-voltage energy, BioPrax™ induces an electrochemical reaction within the implant, effectively disrupting and eliminating biofilms from the implant surface. This targeted approach maximizes treatment efficacy while minimizing collateral damage to surrounding tissues.

Continuation of Standard Care: Following BioPrax™ treatment, healthcare providers can seamlessly transition to the standard of care, ensuring comprehensive patient management. This integrated approach streamlines patient care pathways, optimizing treatment outcomes and enhancing clinical efficiency.

BioPrax™ represents a paradigm shift in the treatment of implant bacterial biofilm infections, offering a transformative solution that combines simplicity, effectiveness, and minimally invasive techniques. As a beacon of hope for patients and healthcare providers, BioPrax™ embodies the relentless pursuit of innovation and excellence in infection control.

About | Wayne Bacon

Wayne Bacon serves as the Co-Founder, President, and Chief Executive Officer at Garwood Medical Devices, where he brings a wealth of experience in business development and leadership to the table. With a remarkable track record of success, Wayne's journey includes owning and operating Mills Welding & Specialty Gases for 24 years, eventually selling the company to Praxair. Following this, he held the position of Chairman & CEO at ImmunoDiagnostics, a renowned producer of biological research reagents, for 12 years. Wayne's entrepreneurial spirit extends beyond these ventures, as he is also an investor in numerous startups and commercial properties in New York and Virginia.

Beyond his professional endeavors, Wayne is deeply involved in his community, having served on various charitable boards including the Kaleida Health Foundation (as past Treasurer) and the Buffalo Rotary Club (as past President).

Wayne holds an MBA in marketing and a bachelor’s in business administration from the University of Delaware. Driven by his entrepreneurial passion and a commitment to addressing orthopedic implant biofilm infections, Wayne co-founded Garwood Medical Devices. Under his visionary leadership, Garwood has achieved significant milestones, including being awarded four patents with others under prosecution both domestically and internationally. Notably, Garwood's BioPrax™ device has received FDA Breakthrough Device designation, signaling a significant step forward in bringing a revolutionary electronic device and treatment platform to market.